ACET · XBRL financial data

Adicet Bio financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ACET's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	34,334	48,943	71,246	106,043	99,323	99,127
General and administrative	22,760	22,220	26,295	26,533	28,292	22,987
Total operating expenses	57,094	71,163	97,541	152,038	127,615	122,114
Other operating income (expense)	—	—	—	598	221	466
Operating income (loss)	(39,191)	(61,433)	(72,551)	(152,038)	(127,615)	(122,114)
Interest expense	134	176	80	25	4	36
Other income (expense)	(953)	(606)	(919)	(573)	(217)	(430)
Income tax expense (benefit)	(2,815)	(125)	0	0	0	0
Net income (loss)	(36,678)	(61,999)	(69,790)	(142,658)	(117,122)	(116,803)
Earnings per share, basic USD per share	—	(2.00)	(1.70)	(3.31)	(1.33)	(16.95)
Earnings per share, diluted USD per share	—	(2.00)	(1.70)	(3.31)	(1.33)	(16.95)
Weighted average shares, basic thousands of shares	7,320	30,952	41,080	43,042	87,866	6,891
Weighted average shares, diluted thousands of shares	—	30,952	41,080	43,042	87,866	6,891

Fiscal years (ACET's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	84,330	277,544	257,656	159,711	56,495	38,918
Short-term investments	—	—	—	0	—	—
Marketable securities	10,284	0	—	—	—	—
Marketable securities, non-current	0	—	—	—	—	—
Prepaid and other current assets	5,722	4,709	3,382	2,561	3,833	2,396
Total current assets	100,336	282,438	261,038	162,272	180,136	160,926
Property and equipment, net	2,790	14,643	28,710	26,777	22,524	16,532
Right-of-use asset	23,066	20,358	20,269	17,424	14,228	10,927
Goodwill	20,089	19,462	19,462	0	—	—
Total assets	153,835	338,938	330,690	207,295	220,219	192,355
Accounts payable	1,552	3,263	4,404	2,625	4,830	4,739
Total current liabilities	22,479	16,317	19,707	19,287	19,392	21,531
Lease liability, non-current	20,424	19,377	18,531	17,703	14,102	10,910
Total liabilities	44,008	35,809	38,352	37,120	33,610	33,145
Accumulated deficit	(106,325)	(168,324)	(238,114)	(380,772)	(497,894)	(614,697)
Total stockholders' equity	109,827	303,129	292,338	170,175	186,609	159,210
Total liabilities and equity	153,835	338,938	330,690	207,295	220,219	192,355
Common shares outstanding (cover page) thousands of shares	31,780	39,877	42,955	82,154	82,686	9,596

Fiscal years (ACET's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(36,678)	(61,999)	(69,790)	(142,658)	(117,122)	(116,803)
Stock-based compensation	5,263	12,511	17,126	20,259	22,233	14,267
Net cash from operating activities	(41,552)	(51,052)	(44,765)	(93,717)	(92,378)	(95,246)
Purchases of property and equipment	990	13,046	16,782	4,464	1,118	1,738
Net cash from investing activities	115,217	(2,796)	(16,782)	(4,464)	(119,242)	2,393
Proceeds from issuing common stock	—	238,129	0	0	19,266	0
Net cash from financing activities	303	242,685	41,509	236	111,307	75,245
Net change in cash	73,968	188,837	(20,038)	(97,945)	(100,313)	(17,608)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Adicet Bio	33,131	not reported	(19,823)*	9.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.